Background. Pertussis serodiagnosis is increasingly being used in the United States despite the lack of a US Food and Drug Administration-approved, commercially available assay. To better understand the utility of these assays in diagnosing pertussis, serology assays were evaluated for analytical parameters and clinical accuracy.
Pertussis, caused by the bacterium Bordetella pertussis, has been on the rise in the United States since the early 2000s, with cases now reaching record-breaking numbers last observed in the 1950s [1] . Outbreaks have occurred in multiple states throughout the country, and both California and Washington experienced statewide epidemics [2, 3] . Reporting of confirmed and suspect cases is based on clinical data and laboratory confirmation. Currently, the Council of State and Territorial Epidemiologists (CSTE) case definition for a pertussis laboratory-confirmed case only includes positive results from bacterial isolation and polymerase chain reaction (PCR)-based assays [4] . Only the state of Massachusetts uses their in-house serology assay as part of their definition for reporting pertussis cases for adolescents and adults with over 2 weeks of cough [5] .
Ongoing surveillance indicates that, regardless of exclusion from the CSTE case definition [4] , serology is used in every state for pertussis diagnosis [6] . However, there are currently no serological assays that are approved by the US Food and Drug Administration (FDA) for pertussis diagnosis. Much is unknown about the serological assays being used for diagnostic purposes. The assays are either laboratory-developed tests (LDTs) that are not available for distribution, or they are sold commercially for research purposes only and contain very little information on their analytical and clinical performance. These assays vary among targets, antibody response, assay conditions, and whether results are qualitative or quantitative.
Serology has been shown to be beneficial for pertussis case confirmation and has been supported in many public health recommendations worldwide [7] [8] [9] . However, obtaining acute and convalescent specimens can be logistically difficult and cost prohibitive, leaving many cases unconfirmed. Furthermore, patients often present too late to obtain an acute serum specimen. Therefore, many countries have moved toward single-point diagnostic assays that required 1 serum sample obtained from a patient during a specified window of time after illness onset [8] [9] [10] [11] [12] [13] .
A serology LDT, which was developed and analytically validated in a collaboration between the FDA and Centers for Disease Control and Prevention (CDC), is currently being used by the CDC's Pertussis and Diphtheria Laboratory as a critical component of their multitest algorithm, which also includes culture and real-time PCR, for the diagnosis of pertussis. It is an immunoglobulin (Ig)G anti-pertussis toxin (PT) enzyme-linked immunosorbent assay (ELISA) [14] with diagnostic cutoffs proposed at 49 and 94 international units (IU)/mL [15] for indeterminate and positive interpretations, respectively. The assay is ideal for retrospective diagnosis for adolescents and adults, as a single-point assay, when the timing, recommended as 2 through 8 weeks after cough onset, is too late for consistently accurate diagnosis by culture or PCR [10, 16] . Public health laboratories are hesitant to routinely adopt similar serology assays for pertussis diagnosis because of potential burden related to case investigations and treatment and, most importantly, the absence of serology in the current CSTE definition.
Our objective was to assess the analytic and clinical accuracy and validity of pertussis serodiagnostic assays in the United States with an overall goal of harmonizing diagnostic methods in the United States and, ultimately, worldwide [13] . A 2-phase approach was followed for this validation study. A pilot test was initially run with a small panel of serum specimens collected from deidentified culture-positive or culture-negative individuals for analysis of analytical parameters: precision, linearity, and accuracy. In the 2nd phase, a larger panel was tested to calculate positive percent agreement (PPA) and negative percent agreement (NPA).
MATERIALS AND METHODS

Study Protocol
In Phase I, analytical parameters were assessed, including linearity, precision, and percentage accuracy. Four plates were run per commercial assay, with 2 plates run per analyst (total = 2 analysts). The 4 assays were run on the same day. To assess intraplate variability, 2 dilutions per sample were run on each plate. The microsphere-based assay was performed by 1 analyst with 1 assay per day and 2 sample dilutions per assay over 4 days.
In Phase II, clinical accuracy was assessed: PPA and NPA were measured. Moreover, in this phase, the serum panel was tested once per assay.
Assay Testing
Thirty-five total assays, including the CDC LDT [14] provided by the manuals. Interpretations of the results were based on the information provided by the enclosed manual for each kit. Assay cutoffs for negative, intermediate, and positive results were typically given and varied greatly between assays. If additional cutoffs were also provided, such as those that recommended 40 IU/mL for intermediate and 100 IU/mL for positive [18] , then the sample interpretations were also analyzed against these cutoffs. Focus Diagnostics followed their clinical cutoffs of PT IgG <45 IU/mL, PT IgA <10 IU/mL, FHA IgG <90 IU/mL, and FHA IgA <50 IU/mL [17] .
Serum Panels
Human sera and plasma were previously collected as either part of public health response or from studies to develop and evaluate pertussis diagnostics. These studies were approved by the necessary institutional review board committees. The Phase I panel consisted of 20 serum specimens: 5 from a 2-fold dilution series of a culture-positive case, 10 from culture-positive cases, 4 from healthy donors, and 1 from the World Health Organization International Reference Standard (WHO IS) 06/140 (NIBSC, UK) [19] . The sera of culture-positive cases were collected at 4-6 weeks after cough onset. The Phase II panel consisted of 226 blood specimens: 70 from culture and/ or PCR-positive symptomatic patients with appropriately timed nasopharyngeal (NP) specimens (ie, NP specimens that were collected at the optimal time for capturing culture and/ or PCR positivity, 0-4 weeks after cough onset); 130 from culture and/or PCR-negative symptomatic patients with appropriately timed NP specimens; and 26 from healthy donors. Four specimens were plasma; the remaining specimens were serum. Timing of case-patient serum specimens included acute and/ or convalescent specimens, with a range of 4-55 days of cough (mean and median = 27 days) for 68 of 70 culture and/or PCRpositive symptomatic patients that had cough onset dates available, and a range of 5-41 days of cough (mean and median = 17 days) for all 130 culture and/or PCR-negative symptomatic patients. Both healthy donors and patients were not previously vaccinated in the last year before blood collection.
Statistical Analyses and Study Exclusions
In Phase I, precision for each assay was calculated for within and between-analyst variability, stratified by analyst, Ig type, and antibody concentration (specifically, IgG anti-PT). For linearity, a 2-fold dilution series of positive sera was made, and concordance correlation coefficients (r c ) were measured to determine the level of agreement between the measured and expected concentrations for each of the dilutions. Expected values for each of the diluted samples in the dilution series originated from the most concentrated sample that could give a result by each assay. Once determined, each sample after dilution was then calculated accordingly for each given assay. An average value was calculated from the 16 replicates for each dilution.
The available IgG anti-PT assays that were calibrated to either Center for Biologics Evaluation and Research lot3 or WHO IS 06/140 were assessed for analytical accuracy by measuring the percentage difference between the observed and expected values of the blinded undiluted specimen of WHO IS 06/140 in the Phase I panel (335 IU/mL). Some assays were not assessed because they were not available at the time of Phase I testing or the upper limit of quantification did not reach 335 IU/mL, the IgG anti-PT value of the WHO IS 06/140. In Phase II, diagnostic interpretations were considered based on the assay's provided cutoffs and/or any additional clinical cutoffs described in the manual, when applicable. The 26 healthy controls were analyzed as either part of the negative clinical sera or were excluded from analysis. Due to the lack of a true reference standard for diagnosing pertussis, either appropriately timed culture and/or PCR positivity or the CDC ELISA results were considered the nonreference standard, and the measurements of agreement between culture and/or PCR or CDC ELISA results with each test assay were henceforth considered the PPA and NPA estimates for each test assay [20] . In the absence of a gold reference standard, these measurements assess the level of agreement between the comparison test and the nonreference standard and are informative in a manner similar to measuring percentage sensitivity and specificity. Intermediate interpretations were analyzed in 3 ways: excluded from the analysis (data not shown), considered positive (Intermediate_positive), or considered negative (Intermediate_negative) [20, 21] .
RESULTS
Overall, 35 assays were assessed representing 43 different antigen-antibody combinations, consisting of ELISAs and a multianalyte, microsphere-based assay (Table 1) . In Phase I, analysis of precision revealed that precision, although predominantly low throughout, was highly variable (Figure 1 ). Between-analyst and between-plate percentage of coefficient of variation (%CV) remained less than 20% for all assays; however, within-analyst %CV varied drastically between assays, suggesting that the type of assay and the analyst can greatly affect precision. When the data from Figure 1 was broken down and stratified by specimen, analyst, and assay type, to analyze precision, a few patterns emerged (Table 2) . Seventy-eight of 1240 (6.3%) potential %CV values, from 17 different assays, had variability >20% for the 2 analysts. Although the total number of values was low for both analysts, Analyst 1 had a higher number of %CV values >20% Analyst 2 (49 vs 29), indicating that Analyst 1 did not perform as well as Analyst 2 during this testing (Table 2 ). This finding suggests that variability can be user dependent. In addition, assays that measured IgM had a much higher percentage of variability than those that measured either IgG or IgA. Finally, samples that contained a higher concentration of antibodies seemed to also give higher variability. Analytical accuracy was measured to assess how well an assay could accurately measure the concentration of a specimen with known concentration. Four assays, at the time of testing, fit the criteria for inclusion in this assessment: Focus, CDC, Genzyme/Sekisui Virotech (GEN PT), and Virion\Serion (VIR PT) ( Table 3 ). The observed results for all 4 assays were ≤15% different from expected values.
For Phase II, PPA and NPA measurements were calculated to assess agreement similar to measuring percentage sensitivity and specificity, respectively. No major differences in PPA and NPA were found between the inclusion and the exclusion of the 26 healthy donors as negative sera (results for exclusion of healthy donor sera not shown). With culture and/or PCR results as the standard, both PPA and NPA varied greatly, depending on the assay (Figure 3) . Overall, IgG anti-PT assays were both high in PPA and NPA. IgA assays overall had lower PPA and NPA, whereas IgM assays had high NPA, but very poor PPA. Results using CDC ELISA results as the standard proved to be highly similar (data not shown). Addition of FHA with PT in IgG assays seemed to increase PPA, but decreased NPA, as observed with the R-Biopharm, Genzyme/Sekisui Virotech, Savyon Diagnostics (SAV), and Virion\Serion IgG assays.
It is interesting to note that 1 particular assay, SAV IgG anti-PT and FHA, provided a "positive" and "high positive" interpretation versus inclusion of an "indeterminate" or "intermediate" result. Therefore, that particular assay was analyzed in 2 ways, either keeping the lower positive cutoff of 10 BU as a positive interpretation or changing it to an intermediate cutoff and making the high positive cutoff of 50 BU the new positive cutoff. Analysis showed that although PPA was unaffected with the change in interpretation, NPA increased dramatically (data not shown). Evaluating the data in this way suggests that a higher cutoff for an assay that has FHA and PT mixed in the same well, where PPA is already high, may also benefit the NPA estimate.
DISCUSSION
A total of 43 antigen-antibody combinations, in ELISA or microsphere-based assays, were analyzed for analytical and clinical accuracy and utility as single-point diagnostics.
Assays were highly variable, depending on precision, linearity, accuracy, and PPA or NPA. Precision measurements indicated that variability of assays is affected by individual analysts, type of Ig analyzed (IgM assays more variable), or antibody concentration (highly concentrated samples produce more variability). The high intra-analyst variability observed is not unexpected, considering that the analysts had no previous experience running these specific assays. It should also be noted that the precision cutoff we applied of 20% was rather stringent. Nevertheless, these results suggests that the expertise of the analyst with serology and the specific experience of a particular assay could greatly affect results. In addition, previous comparisons between different assays suggested that assay characteristics and sample antibody concentrations needed to be considered when assessing assay precision [22] , and our findings to date continue to support this conclusion. It is interesting to note that no assay protocol provided information on the quality of the antigens or the sources from where they came, making it difficult to ascertain whether differences observed here may also be due to antigen purity. Regardless of the assay implemented, analysts should follow proper procedures for training, competency, and proficiency and be well versed in the methodology. When compared with both nonreference standards, IgG anti-PT ELISAs seemed to be high in both PPA and NPA compared with IgA or IgM assays. These findings strongly suggest that IgG anti-PT ELISAs will provide acceptable clinical sensitivity and specificity as a stand-alone, single-point assay. On the contrary, the PPA and NPA values were highly variable with IgA assays, never reaching the levels of IgG assays, and the PPA of IgM assays proved to be exceptionally poor, suggesting that IgM assays would not be useful in diagnosing pertussis (Figure 3 ). Immunoglobulin A assays tested previously showed similar results, further suggesting the use of IgG assays as the optimal serodiagnostic tool [12, 23] . Our results also showed that the inclusion of additional antigens in IgG assays, such as FHA with PT, increased PPA but drastically decreased NPA (Figure 3) . In other findings, FHA was not found to increase positivity compared with PT alone; in fact, positivity was observed in high concentrations in the control group, suggesting nonspecific cross-reactivity [24] . For serology, a tool that is ideal for retrospective diagnosis, high specificity is critical to avoid falsely attributing unknown outbreaks and cases to pertussis, as well as unnecessary follow-up of case contacts and prophylaxis measures. Furthermore, quantitative results for IgG anti-PT ELISAs that were calibrated to an international reference standard proved to be highly accurate, suggesting that assay results may be comparable between different assays. Previous publications have also suggested that different assays can be harmonized if assays are rigorously validated, calibrated to a reference standard, and use highly purified antigens [25, 26] . Indeed, production of these assays does seem to be increasing, because between the time of testing of Phase I and Phase II panels, the number of commercially available, calibrated, IgG anti-PT only kits doubled, likely due to the high demand for them [8, 13, 23, 27, 28] .
A valid concern does arise with the use of anti-PT ELISAs and the recommended 1-time tetanus-diphtheria-acellular pertussis (Tdap) booster for adolescents and adults. If serodiagnosis is used for a clinically suspect adolescent or adult that was previously vaccinated with Tdap, it may be difficult to discern whether the observed titers are due to infection, vaccination, or a combination of both. A previous study following healthy adult subjects who were vaccinated with Tdap for up to 2 years postvaccination determined that titers did not reach the high diagnostic cutoffs for acute infection, suggesting that vaccination should not confound diagnostic results [29] . Nonetheless, waiting periods from 6 months to 3 years postvaccination have been recommended to ensure the likelihood of decreased antibody titers [8, 9, 29] .
CONCLUSIONS
In conclusion, the qualities of the kits that are deemed most promising for diagnosing pertussis are that they measure IgG antibodies against PT only and that they are calibrated to a reference, because these assays show (1) high PPA compared with IgA and IgM assays, (2) higher NPA compared with ELISAs with multiple coating antigens, and (3) the potential to compare results with other calibrated assays. Awareness among clinicians and public health specialists about the advantages and limitations of pertussis serodiagnostics is increasing. One can speculate that in the United States, a similar harmonization of serodiagnostics will occur as it did with PCR diagnostics in the last decade [30, 31] . When PCR and bacterial isolation during the later phases of disease are severely limited, serology can be highly effective when clinically validated assays are used [9] . Our findings provide insight to manufacturers about the ideal assay characteristics for pertussis serodiagnosis, hopefully leading the way to finding clinically validated FDA-approved assays on the US market in the near future. Serology, combined with sound guidance and informed decisions, may offer the complementary diagnostic tool for older, vaccinated populations, allowing public health officials to more accurately assess the burden of pertussis across the age spectrum.
Notes
